TABLE 1.
Patient characteristics
| Group | Patient | Age (yr) | Gendera | Antiretroviral treatmentb | Plasma viremia (RNA copies/ml) in sample:
|
Absolute CD4 count (%) in sample:
|
Cell fractions collectedc:
|
|||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 1 | 2 | 1 | 2 | |||||
| A | 03 | 42 | m | d4T, NFV, 3TC | <6 | 956 (35) | 1, 2, 5 | |||
| 04 | 48 | m | ABC, d4T, LPV/r | 2280 | 90d | 372 (13) | 430 (16)d | 1-5 | 1, 2, 6 | |
| 07 | 52 | m | AZT, 3TC, RTV | <8 | <2d | 587 (29) | 444 (27)d | 1-5 | 1, 2, 6 | |
| 08 | 50 | m | AZT, 3TC, LPV/r | <12 | 575 (32) | 1-5 | ||||
| 13 | 42 | f | TDF, FTC, ATV/r | <1 | 48 | 437 (25) | 523 (29) | 1-5 | 1, 2, 6 | |
| 14 | 33 | f | ddI, TDF, NVP | <2 | <2 | 426 (26) | 236 (28)d | 1-5 | 1, 2, 6 | |
| B | 05 | 37 | m | 76,300 | 16,900d | 358 (29) | 429 (27)d | 1-5 | 1, 2, 6 | |
| 06 | 38 | m | 62,000 | 83,000d | 423 (24) | 249 (15)d | 1-5 | 1, 2, 6 | ||
| 10 | 34 | m | 121,000 | 101,000d | 474 (24) | 433 (22) | 1-5 | 1, 2, 6 | ||
| 11 | 73 | f | 1,225,000 | 177 (9) | 1-5 | 1, 2, 6 | ||||
| 15 | 45 | m | 66,500 | 60,500d | 295 (13) | 266 (14)d | 1-5 | |||
| 16 | 33 | m | 92,800 | 111,000d | 403 (38) | 328 (37)d | 1-5 | 1, 2, 6 | ||
a
m, male; f, female.
b
Abbreviations used for antiretroviral drugs: d4T, stavudine; NFV, nelfinavir; 3TC, lamivudine; ABC, abacavir; LPV/r, lopinavir/ritonavir; AZT, zidovudine; RTV, ritonavir; TDF, tenofovir; FTC, emtricitabine; ATV/r, atazanavir-ritonavir; ddI, didanosine; NVP, nevirapine.
c
1, PBMC; 2, CD4+ T cells; 3, resting CD4+ T cells; 4, activated CD4+ T cells; 5, monocytes; 6, CD4−/CD8− T cells.
d
Value extrapolated from closely adjacent time points.